> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Glaxo MenABCWY Vaccine Hits 11 Endpoints
- URL: https://www.fdaweb.com/glaxo-menabcwy-vaccine-hits-11-endpoints/
- Published: 2023-03-16T12:00:00.000Z
- Updated: 2026-09-14T18:19:54.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5153999

GlaxoSmithKline says its meningococcal ABCWY vaccine candidate met all 11 primary endpoints in a pivotal Phase 3 trial and was well tolerated with a safety profile consistent with the company’s Bexsero and Menveo meningococcal vaccines. A company [statement](https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-pivotal-phase-iii-data-for-5-in-1-meningococcal-abcwy-vaccine-candidate/?ref=fdaweb.com) says the primary endpoint data demonstrated non-inferiority compared to Bexsero and Menveo in individuals 10-25 years old, with the 5-in-1 vaccine candidate eliciting a clinically meaningful immune response.

“If approved,” the statement says, “this 5-in-1 vaccine candidate could provide the broadest meningococcal serogroup coverage and could lead to a simplified immunization schedule.”